We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Globavir, Bio-Rad Partner
News

Globavir, Bio-Rad Partner

Globavir, Bio-Rad Partner
News

Globavir, Bio-Rad Partner

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Globavir, Bio-Rad Partner"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Globavir Biosciences Inc has announced a partnership with Bio-Rad Laboratories Inc. Under the terms of the agreement, Bio-Rad will license Globavir's PanGlobTM dengue detection technology for use in an assay that includes dengue virus detection. Financial terms of the agreement were not disclosed.

The PanGlob assay, originally developed by Stanford University researchers, includes improved diagnostic sensitivity, efficacy across all four dengue serotypes, and enhanced specificity for dengue over related viruses. This advanced technology reduces the risk of incorrect results.

"Infectious disease outbreaks are a threat to human health with the potential of quickly reaching an epidemic level," said Globavir CEO Dr. Shalabh Gupta. "Correct diagnosis of these types of diseases is the crucial first step toward effective patient care and surveillance. Globavir is excited to lend our dengue technology toward the creation of this important assay."

"Bio-Rad is pleased to partner with Globavir for a dengue assay that provides improved sensitivity and specificity in detecting this virus," said Bio-Rad President Clinical Diagnostics Group John Hertia.

Advertisement